PGEN Stock Recent News

–   PRGN-2012 has potential to be first FDA-approved therapeutic for treatment of RRP, a rare and devastating chronic disease  – –   Company completed BLA submission for PRGN-2012 for treatment of adults with RRP  – –   Commercial readiness activities underway in anticipation of potential launch of PRGN-2012; Company started 2025 with approximately $100 million cash on-hand* with cash runway well into 2026, beyond the anticipated launch in the second half of 2025  – –   According to recently updated internal analysis derived from review of claims data, the market opportunity for PRGN-2012 in RRP is estimated to be approximately 27,000 adult patients in the US  – –   Immense market potential for AdenoVerse platform in other HPV6/11-driven indications, such as genital warts, which has significant unmet need with annual global incidence of more than 4 million and prevalence of more than 25 million, and HPV16/18-driven indications, such as cervical cancer a

GERMANTOWN, Md. , Jan. 9, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present at the 43rd Annual J.P.

The upside in Precigen's stock comes after it completes the rolling submission of an FDA filing for its first potentially marketed product.

GERMANTOWN, Md. , Sept. 16, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a fireside chat on Wednesday, September 18, 2024 from 9:45 to 10:15 AM ET at the 2024 Cantor Global Healthcare Conference taking place September 17 to 19, 2024 in New York.

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Thursday.

Precigen, Inc. (NASDAQ:PGEN ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Steven Harasym - VP, IR Helen Sabzevari - President & CEO Harry Thomasian - CFO Phil Tennant - Chief Commercial Officer Rutul Shah - COO Conference Call Participants Carolina Ibanez Ventoso - Stifel Jason Butler - Citizens JMP Swayampakula Ramakanth - H.C. Wainwright Jennifer Kim - Cantor Fitzgerald Operator Good evening and welcome to the Precigen's Second Quarter and First Half 2024 Financial Results Call.

Precigen, Inc. (PGEN) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.

– In June 2024, the Company announced groundbreaking pivotal study data for PRGN-2012 gene therapy at the 2024 ASCO annual meeting in which more than half of RRP patients achieved Complete Response – – In July 2024, the Company appointed Phil Tennant as Chief Commercial Officer to spearhead potential PRGN-2012 commercial launch – – In August 2024, the Company announced a strategic reprioritization of its pipeline to focus on advancement of its lead program, PRGN-2012 in RRP – – PRGN-2012 rolling BLA submission, under an accelerated approval pathway, is anticipated in the second half of 2024; the Company has initiated enrollment in the confirmatory clinical trial of PRGN-2012 – – In August 2024, the Company strengthened its cash position by raising approximately $31.4 million via a public offering of common stoc k – GERMANTOWN, Md. , Aug. 14, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovati

GERMANTOWN, Md. , Aug. 9, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2024 financial results and provide business updates on Wednesday, August 14, 2024.

GERMANTOWN, Md. , Aug. 7, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 35,294,118 shares of its common stock at a public offering price of $0.85 per share.